Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Smith & Nephew SNATS (SNN) Stock Price

Press coverage about Smith & Nephew SNATS (NYSE:SNN) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Smith & Nephew SNATS earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.7799828971578 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Smith & Nephew SNATS (SNN) traded up $0.04 during mid-day trading on Wednesday, hitting $35.95. The stock had a trading volume of 276,764 shares, compared to its average volume of 494,509. The company has a current ratio of 2.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Smith & Nephew SNATS has a fifty-two week low of $28.45 and a fifty-two week high of $40.43.

A number of brokerages have recently weighed in on SNN. Zacks Investment Research raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Wednesday, October 18th. Canaccord Genuity began coverage on Smith & Nephew SNATS in a report on Wednesday, October 11th. They issued a “buy” rating and a $42.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $42.50.

WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Insider Buying and Selling by Quarter for Smith & Nephew SNATS (NYSE:SNN)

What are top analysts saying about Smith & Nephew SNATS Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Smith & Nephew SNATS Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit